Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Glomerulonephritis
How do you decide when to stop immunosuppression in a patient with granulomatosis with polyangiitis who is on dialysis, has not yet recovered renal function, but has shown improvement in ANCA levels?
Related Questions
Would you consider initiating eculizumab without plasmapheresis as initial therapy for a patient with renal TMA who has a low suspicion of TTP based on a scoring algorithm?
How would you approach a patient with class III and V lupus nephritis, already on HCQ, MMF, voclosporin and losartan, but has continued proteinuria not yet attaining complete renal response?
What do you feel are the potential barriers to widespread use of obinutuzumab in proliferative lupus nephritis?
How would you treat idiopathic isolated renal TMA diagnosed on renal biopsy without evidence of MAHA?
What steroid regimen do you typically use for induction therapy in patients with lupus nephritis?
Do you wait until serum anti-GBM antibody titers are undetectable before hospital discharge in a patient with anti-GBM antibody disease with renal involvement who is receiving daily plasmapheresis, cyclophosphamide, and steroids?
How do various therapeutic approaches for IgA nephropathy target the different stages of the four-hit hypothesis?
What would be your approach to managing severe ANCA-associated vasculitis in a patient who is also septic from a bacterial infection?
What is your recommended sequence of therapies for achieving optimal proteinuria reduction in IgA nephropathy, especially in light of the recent approvals of sparsentan, delayed-release budesonide, and iptacopan?
What are your top takeaways from ASN 2024?
